AAPG (AAPG) Stock

Healthcare · Biotechnology · Member of Other US Stocks

AAPG (AAPG) closed at USD 14.85 on 2026-10-14, a change of -55.7 % over the past year, with a market capitalization of USD 1.37B.

AAPG recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

AAPG key figures

Previous close

USD 14.85 (2026-10-14)

1-year change

-55.7 %

Market cap

USD 1.37B

Enterprise value

USD 1.58B

P/E ratio (trailing)

-6.68

P/E ratio (forward)

-22.59

EPS (trailing)

-2.20

EPS (forward)

-0.65

PEG ratio

n/a

Price to book

16.49

Revenue growth

29.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.45

Employees

828

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About AAPG

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for AAPG and compare it with other stocks.